This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is Aytu Bioscience (AYTU) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (AYTU) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Middlesex Water, Howard Hughes, Ubiquiti, Aptose and Aytu
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Middlesex Water, Howard Hughes, Ubiquiti, Aptose and Aytu
Sarepta Stock Up Almost 40% This Year So Far: Here's Why
by Zacks Equity Research
Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is nearing approval. The company is also developing gene therapies.
Bond Yields Plunge Globally on Slowdown Fears: 5 Safe Picks
by Nalak Das
A growing number of central banks are giving signals for pursuing easy monetary policy in order to raise inflation and generate economic growth.
Myriad Genetics Announces Study Results Of myRisk Cancer Test
by Zacks Equity Research
The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.
Is Aytu Bioscience (AYTU) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (AYTU) Outperforming Other Medical Stocks This Year?
All You Need to Know About Aytu Bioscience, Inc. (AYTU) Rating Upgrade to Strong Buy
by Zacks Equity Research
Aytu Bioscience, Inc. (AYTU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aytu Bioscience, Inc. (AYTU) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aytu Bioscience, Inc. (AYTU) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).